Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

Life-threatening "breakthrough" cases of critical COVID-19 are attributed to poor or waning antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting auto-Abs neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in unvaccinated...

Full description

Bibliographic Details
Main Authors:	Bastard, P, Vazquez, SE, Liu, J, Laurie, MT, Wang, CY, Gervais, A, Le Voyer, T, Bizien, L, Zamecnik, C, Philippot, Q, Rosain, J, Catherinot, E, Willmore, A, Mitchell, AM, Bair, R, Garçon, P, Kenney, H, Fekkar, A, Salagianni, M, Poulakou, G, Siouti, E, Sahanic, S, Tancevski, I, Weiss, G, Nagl, L, Manry, J, Duvlis, S, Arroyo-Sánchez, D, Paz Artal, E, Rubio, L, Perani, C, Bezzi, M, Sottini, A, Quaresima, V, Roussel, L, Vinh, DC, Reyes, LF, Garzaro, M, Hatipoglu, N, Boutboul, D, Tandjaoui-Lambiotte, Y, Borghesi, A, Aliberti, A, Cassaniti, I, Venet, F, Monneret, G, Halwani, R, Sharif-Askari, NS, Danielson, J, Constantinescu, S
Other Authors:	COVID HGE Consortium
Format:	Journal article
Language:	English
Published:	American Association for the Advancement of Science 2022

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

Similar Items